12:00 AM
 | 
Mar 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Silenor doxepin: QT/QTc study data

Data from a U.S. QT/QTc study in 200 patients showed that 6 and 50 mg Silenor met the primary endpoint of no difference on QTc interval prolongation compared with placebo. The company also said the compound did not...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >